

# Hans-Georg Eichler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3442262/publications.pdf>

Version: 2024-02-01

11  
papers

1,452  
citations

1307594

7  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

2055  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1212-1218.	4.7	97
2	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e83.	0.5	10
3	Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 711-731.	1.4	32
4	Precision reimbursement for precision medicine: using real world evidence to evolve from trialâ€”project to trackâ€”pay to learnâ€”predict.. <i>Clinical Pharmacology and Therapeutics</i> , 2021, , .	4.7	5
5	Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testingâ€”Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. <i>Value in Health</i> , 2020, 23, 1128-1136.	0.3	68
6	Clinical trial publications: A sufficient basis for healthcare decisions?. <i>European Journal of Internal Medicine</i> , 2020, 71, 13-14.	2.2	4
7	Good practices for realâ€”world data studies of treatment and/or comparative effectiveness: Recommendations from the joint <sc>ISPORâ€”SPE</sc> Special Task Force on realâ€”world evidence in health care decision making. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1033-1039.	1.9	251
8	Drug Regulation and Pricing â€” Can Regulators Influence Affordability?. <i>New England Journal of Medicine</i> , 2016, 374, 1807-1809.	27.0	39
9	Bridging the efficacyâ€”effectiveness gap: a regulator's perspective on addressing variability of drug response. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 495-506.	46.4	293
10	Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers. <i>European Journal of Health Economics</i> , 2006, 7, 129-136.	2.8	6
11	Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?. <i>Value in Health</i> , 2004, 7, 518-528.	0.3	647